kidney issues with tirzepatide GLP therapies have established themselves as kidney-protective in type 2 diabetes and high risk of disease. This new post-hoc analysis of SURPASS-CVOT's kidney outcomes shows greater kidney protection (#mounjaro) Kidney Outcomes in SURPASS: Exploring
Description
Added Pyridoxine (Vitamin B6) helps mitigate nausea and support energy metabolism
Taking a break from semaglutide requires medical guidance based on individual response patterns, metabolic markers, and treatment goals
The Pharmaceutical Journal has shared latest updates for clinicians and investigated supply issues around private vaccinations
Individualized Weight Management
lifespan depends on usage and care
Why the Maintenance Phase Matters for Long-Term Results After achieving significant weight loss through GLP-1 therapy, the next stage plays a substantial role in preserving health benefits
